Theriva Biologics' VCN-01 Shows Survival Benefits in Pancreatic…

Event summary

Theriva Biologics published Phase 2b VIRAGE trial results in Nature Medicine, showing improved overall survival, progression-free survival, and duration of response for VCN-01 combined with standard-of-care chemotherapy in metastatic pancreatic cancer.
The study suggests an immune-mediated mechanism of action for VCN-01 beyond its stroma-degrading effects.
Theriva has initiated the VIRAGE2 Phase 2a trial to evaluate more frequent VCN-01 dosing, with enrollment expected to complete by the second half of 2026.
VCN-01 has received Orphan Drug and Fast Track designations for metastatic pancreatic cancer and retinoblastoma.

The big picture

Theriva Biologics' positive Phase 2b results for VCN-01 in metastatic pancreatic cancer position the company to advance into later-stage trials, potentially offering a new treatment option in a disease with high unmet need. The focus on more frequent dosing and the exploration of VCN-01 in other cancer types, including retinoblastoma, highlight the company's strategic shift towards broadening its therapeutic applications. The engagement with regulatory agencies for both pancreatic cancer and retinoblastoma underscores the potential for accelerated development pathways.

What we're watching

Clinical Efficacy: Whether more frequent VCN-01 dosing in the VIRAGE2 trial can further improve clinical outcomes in metastatic pancreatic cancer patients.
Regulatory Pathway: The pace at which Theriva can finalize the design of a potential Phase 2/3 study for VCN-01 in retinoblastoma with the FDA.
Market Potential: How the Rare Pediatric Disease designation and potential Priority Review Voucher could accelerate VCN-01's development and commercialization.